Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 381

1.

Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.

Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E.

Ann Surg Oncol. 2008 Dec;15(12):3521-31. doi: 10.1245/s10434-008-0152-3. Epub 2008 Oct 2.

PMID:
18830756
2.

Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.

Moureau-Zabotto L, Phélip JM, Afchain P, Mineur L, André T, Vendrely V, Lledo G, Dupuis O, Huguet F, Touboul E, Balosso J, Louvet C.

J Clin Oncol. 2008 Mar 1;26(7):1080-5. doi: 10.1200/JCO.2007.12.8223.

PMID:
18309942
3.

Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.

Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e749-57. doi: 10.1016/j.ijrobp.2010.10.034. Epub 2011 Mar 21.

PMID:
21420250
4.

Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.

Kurt E, Kurt M, Kanat O, Cetintas SK, Aygun S, Palazoglu T, Ozkan L, Evrensel T, Kaya E, Manavoglu O.

Tumori. 2006 Nov-Dec;92(6):481-6.

PMID:
17260487
5.

Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study.

Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, Chang FY, Lee SD, Yen SH.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):98-104.

PMID:
12909221
6.

Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.

Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M.

Cancer. 2013 Jan 15;119(2):277-84. doi: 10.1002/cncr.27736. Epub 2012 Jul 6.

7.

Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.

Tsujie M, Nakamori S, Tanaka E, Nagano H, Umeshita K, Dono K, Sakon M, Inoue T, Inoue T, Monden M.

Jpn J Clin Oncol. 2006 Aug;36(8):504-10. Epub 2006 Jul 19.

PMID:
16855011
8.

Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.

Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, Kim TY, Bang YJ, Ha SW, Yoon YB.

Cancer Chemother Pharmacol. 2012 Sep;70(3):381-9. doi: 10.1007/s00280-012-1918-7. Epub 2012 Jul 18.

PMID:
22806305
9.

Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.

Hudson E, Hurt C, Mort D, Brewster AE, Iqbal N, Joseph G, Crosby TD, Mukherjee S.

Clin Oncol (R Coll Radiol). 2010 Feb;22(1):27-35. doi: 10.1016/j.clon.2009.09.024. Epub 2009 Nov 5.

PMID:
19896352
10.
11.

Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ.

Am J Clin Oncol. 2016 Feb;39(1):1-7. doi: 10.1097/COC.0000000000000003.

PMID:
26132367
12.

[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].

Gong JF, Zhang XD, Li J, Di LJ, Jin ML, Shen L.

Ai Zheng. 2007 Aug;26(8):890-4. Chinese.

PMID:
17697554
13.

Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.

Barone C, Cassano A, Corsi DC, Pozzo C, Longo R, Schinzari G, Quirino M, Battelli C, Basso M.

Oncology. 2003;64(2):139-45.

PMID:
12566911
14.
15.

[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].

Barhoumi M, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L, Chauffert B.

Cancer Radiother. 2011 Jun;15(3):182-91. doi: 10.1016/j.canrad.2010.10.001. Epub 2011 Feb 10. French.

PMID:
21315644
16.
17.

Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.

Taira K, Boku N, Fukutomi A, Onozawa Y, Hironaka S, Yoshino T, Yasui H, Yamazaki K, Taku K, Hashimoto T, Nishimura T.

J Gastroenterol. 2008;43(11):875-80. doi: 10.1007/s00535-008-2236-z. Epub 2008 Nov 18.

PMID:
19012041
18.

Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer.

Huang PI, Chao Y, Li CP, Lee RC, Chi KH, Shiau CY, Wang LW, Yen SH.

Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):159-65. doi: 10.1016/j.ijrobp.2008.04.012. Epub 2008 May 26.

PMID:
18508203
19.

Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.

Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1426-32. doi: 10.1016/j.ijrobp.2009.06.053. Epub 2010 Jan 7.

PMID:
20056351
20.

Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.

Ogawa K, Ito Y, Hirokawa N, Shibuya K, Kokubo M, Ogo E, Shibuya H, Saito T, Onishi H, Karasawa K, Nemoto K, Nishimura Y; Japanese Radiation Oncology Study Group Working Subgroup of Gastrointestinal Cancers..

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):559-65. doi: 10.1016/j.ijrobp.2011.07.013. Epub 2011 Oct 20.

PMID:
22019243

Supplemental Content

Support Center